Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISAL 2019 | AML research at Dana-Farber: updates from Richard Stone

Richard Stone • 14 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies

Ongoing acute leukemia research at Dana-Farber Cancer Institute, Boston, MA, is discussed here by Richard Stone, MD, at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Stone highlights immuno-oncology and targeted agents being investigated, including the inhibition of E-selectin.

More from Richard Stone

Approaches to managing FLT3-mutant AML 12:59
Approaches to managing FLT3-mutant AML
Alexander Perl et al. • 20 Sep 2025
Novel targets, treatments, and combinations in AML
David Sallman et al. • 29 Sep 2022
Novel treatments & combinations in AML: mechanisms of resistance to venetoclax & approaching R/R disease
Marina Konopleva et al. • 1 Oct 2024
ISAL session highlights: targeting CD123, CD47 & TP53 in AML 2:02
ISAL session highlights: targeting CD123, CD47 & TP53 in AML
Richard Stone • 21 Mar 2023

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals